DOI QR코드

DOI QR Code

Differences in Regional Glucose Metabolism of the Brain Measured with F-18-FDG-PET in Patients with Essential Tremor According to Their Response to Beta-Blockers

  • Song, In-Uk (Department of Neurology, College of Medicine, The Catholic University of Korea) ;
  • Ha, Sang-Won (Department of Neurology, Veterans Hospital, Seoul Medical Center) ;
  • Yang, Young-Soon (Department of Neurology, Veterans Hospital, Seoul Medical Center) ;
  • Chung, Yong-An (Department of Radiology, College of Medicine, The Catholic University of Korea)
  • 투고 : 2014.12.30
  • 심사 : 2015.06.24
  • 발행 : 2015.09.01

초록

Objective: In this study, there was an investigation as to whether there is a functional difference in essential tremor (ET), according to responses to beta-blockers, by evaluating regional changes in cerebral glucose metabolism. Materials and Methods: Seventeen male patients with ET were recruited and categorized into two groups: 8 that responded to medical therapy (group A); and 9 that did not respond to medical therapy (group B). Eleven age-sex matched healthy control male subjects were also included in this study. All subjects underwent F-18 fluorodeoxyglucose (FDG)-PET, and evaluated for their severity of tremor symptoms, which were measured as a score on the Fahn-Tolosa-Marin tremor rating scale (FTM). The FDG-PET images were analyzed using a statistical parametric mapping program. Results: The mean FTM score 6 months after the initiation of propranolol therapy was significantly lower in group A (18.13 > 8.13), compared with group B (14.67 = 14.67). The glucose metabolism in group A in the left basal ganglia was seen to be decreased, compared with group B. The ET showed a more significantly decreased glucose metabolism in both the fronto-temporo-occipital lobes, precuneus of right parietal lobe, and both cerebellums compared with the healthy controls. Conclusion: Essential tremor is caused by electrophysiological disturbances within the cortical-cerebellar networks and degenerative process of the cerebellum. Furthermore, ET may have different pathophysiologies in terms of the origin of disease according to the response to first-line therapy.

키워드

참고문헌

  1. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007;22:279-282 https://doi.org/10.1002/mds.21282
  2. Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Curr Neurol Neurosci Rep 2002;2:324-330 https://doi.org/10.1007/s11910-002-0008-3
  3. Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord 2002;17:638-644 https://doi.org/10.1002/mds.10221
  4. Song IU, Kim JS, Lee SB, Ryu SY, An JY, Kim HT, et al. Effects of zonisamide on isolated head tremor. Eur J Neurol 2008;15:1212-1215 https://doi.org/10.1111/j.1468-1331.2008.02296.x
  5. Louis ED, Shungu DC, Chan S, Mao X, Jurewicz EC, Watner D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci Lett 2002;333:17-20 https://doi.org/10.1016/S0304-3940(02)00966-7
  6. Quattrone A, Cerasa A, Messina D, Nicoletti G, Hagberg GE, Lemieux L, et al. Essential head tremor is associated with cerebellar vermis atrophy: a volumetric and voxel-based morphometry MR imaging study. AJNR Am J Neuroradiol 2008;29:1692-1697 https://doi.org/10.3174/ajnr.A1190
  7. Jankovic J. Essential tremor: clinical characteristics. Neurology 2000;54(11 Suppl 4):S21-S25
  8. Groenewegen HJ. The basal ganglia and motor control. Neural Plast 2003;10:107-120 https://doi.org/10.1155/NP.2003.107
  9. Gerfen CR. Molecular effects of dopamine on striatalprojection pathways. Trends Neurosci 2000;23(10 Suppl):S64-S70 https://doi.org/10.1016/S1471-1931(00)00019-7
  10. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23(10 Suppl):S71-S77 https://doi.org/10.1016/S1471-1931(00)00027-6

피인용 문헌

  1. Progressive gait ataxia following deep brain stimulation for essential tremor: adverse effect or lack of efficacy? vol.139, pp.11, 2016, https://doi.org/10.1093/brain/aww223
  2. Essential Tremor: What We Can Learn from Current Pharmacotherapy vol.6, pp.None, 2016, https://doi.org/10.7916/d8k35tc3
  3. Structural differences in impaired verbal fluency in essential tremor patients compared to healthy controls vol.7, pp.7, 2015, https://doi.org/10.1002/brb3.722
  4. General and selective brain connectivity alterations in essential tremor: A resting state fMRI study vol.16, pp.None, 2015, https://doi.org/10.1016/j.nicl.2017.06.004
  5. A Voxel-Wise Meta-Analysis of Gray Matter Abnormalities in Essential Tremor vol.9, pp.None, 2015, https://doi.org/10.3389/fneur.2018.00495
  6. Metabolic Positron Emission Tomography Response to Gamma Knife of the Ventral Intermediate Nucleus in Essential Tremor vol.84, pp.6, 2015, https://doi.org/10.1093/neuros/nyy340
  7. Current and Future Neuropharmacological Options for the Treatment of Essential Tremor vol.18, pp.6, 2015, https://doi.org/10.2174/1570159x18666200124145743
  8. The Molecular Neuroimaging of Tremor vol.21, pp.12, 2015, https://doi.org/10.1007/s11910-021-01157-4
  9. The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models vol.11, pp.12, 2021, https://doi.org/10.3390/biom11121813